Citations

Clear

6273 citation(s) found for "To, Andrew".

A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations
Wheless, Margaret C. , Gbolahan, Olumide B., Waechter, Blake, Ou, Fang‐Shu , Nixon, Andrew B. , Wilson, Luke, Ou, Fang-Shu , Nixon, Andrew B , Gbolahan, Olumide B , Zemla, Tyler , Hubbard, Joleen M. , Strickler, John H. , Wilson, Luke, Bekaii‐Saab, Tanios , Ciombor, Kristen K.

Mayo Clinic

The Oncologist | June 14, 2025 | Volume: 30 | Issue: 6 | Pages: No page available

10.1093/oncolo/oyaf069 | PMID 40515475 Get It

Abstract Background FGFR alterations are known to be driver alterations in several tumor types. We aimed to assess the efficacy of pemigatinib, an oral FGFR1-3 inhibitor, in patients with metastatic or unresectable colorectal cancer whose tumors harbored FGF/FGFR alterations. Patients and Methods The ACCRU-GI-1701 is a single-arm phase II trial which enrolled patients with previously treated FGF/FGFR-altered metastatic colorectal cancer to receive oral pemigatinib daily in 21-day cycles. The primary endpoint is objective response. Secondary endpoints include clinical benefit, progression-free survival, overall survival, quality of life, and adverse events (AEs). This trial was registered with ClinicalTrials.gov (NCT04096417). Results Of the 14 patients included in the interim analysis, the objective response rate as well as clinical benefit rate were 0%. Given these results, the trial closed to enrollment after stage one due to futility. A total of 42.9% of patients had at least one grade 3 or higher AE, the most common being anemia and fatigue. Conclusion Pemigatinib monotherapy did not lead to objective responses in patients with chemorefractory metastatic colorectal cancer harboring FGF/FGFR alterations, although it was overall relatively well tolerated with no new safety signals. Notably, 93% (n = 13) of patients had only FGF/FGFR mutations and amplifications; one patient had an FGFR3-WHSC1 fusion at a low cfDNA percentage (0.02%).
Knowledge Self-Assessment Engagement and Family Medicine Board Examination Outcomes
Wingrove, Peter , Bazemore, Andrew , Wang, Ting , Stelter, Keith, Price, David W. , Stelter, Keith

Mayo Clinic

Family Medicine | June 13, 2025 | Volume: 57 | Issue: 7 | Pages: 500-507

10.22454/fammed.2025.200510 | PMID 40526852 Get It

Background and Objectives: Evidence on the relationship between formative assessment engagement and summative assessment outcomes in practicing physicians is sparse. We evaluated the relationship between engagement in the American Board of Family Medicine (ABFM) formative Continuous Knowledge Self-Assessment (CKSA) and performance on high-stakes summative assessments. Methods: This retrospective cohort study included 24,926 ABFM diplomates who completed CKSA modules and summative assessments between 2017 and 2023. We analyzed CKSA engagement metrics—such as the number of quarters completed, time of completion, and self-reported confidence—against performance on summative assessments, measured by z scores. Multivariable regression models controlled for demographic factors and prior assessment performance. Results: The overall cohort summative assessment pass rate during the study period was 90.3%. Greater CKSA engagement was strongly associated with higher summative assessment performance. Diplomates who completed all four CKSA quarters had significantly higher summative assessment z scores than those completing fewer quarters (P<.001). Early CKSA completion and spending more time on low-confidence questions were also positively correlated with both CKSA and summative assessment scores (P<.001). These effects were observed across different levels of prior exam performance. Conclusions: Engagement in formative assessments like CKSA, particularly early and consistent participation and reviewing incorrect or low-confidence questions, is linked to better outcomes on high-stakes assessments. Future research should explore the mechanisms underlying these associations and consider developing an index of engagement to identify physicians at risk of poor performance. Incorporating structured, longitudinal self-assessments like CKSA into certification requirements could enhance continuous learning and improve summative exam readiness.
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma
Zhang, Weiwei , Sharma, Sunandini , Shah, Roshani , Lone, Waseem , Mehmood, Syed Karman, Chawla, Ravneet Singh, Cappelli, Luca Vincenzo , Heavican‐Foral, Tayla B. , Cannatella, Jeffrey J. , Amador, Catalina, Arif, Aiza, Lim, Soon Thye , Ong, Choon Kiat , Du, Ming‐Qing , Perry, Anamarija M. , Greiner, Timothy C. , Fu, Kai , Trøen, Gunhild, Weinstock, David M. , Laginestra, Antonella, Kim, KyeongJin , Vose, Julie, Weisenburger, Dennis D., Davé, Sandeep S. , Khoury, Joseph D. , Chan, Wing C., Iqbal, Javeed , Bouska, Alyssa , Lone, Waseem G , Cappelli, Luca Vincenzo , Ong, Choon Kiat , Weinstock, David M , Iqbal, Javeed , Holte, Harald , Shah, Rauf A., Soma, Mahfuza Afroz , Yang, Ruimeng , Liu, Xuxiang , Chawla, Ravneet Singh, Fiore, Danilo , Gong, Qiang , Heavican, Tayla B., Smith, Lynette M. , Feldman, Andrew L. , Leval, Laurence de , Vodák, Daniel , Nakken, Sigve , Delabie, Jan , Pileri, Stefano , Pajvani, Utpal B. , Weisenburger, Dennis D. , Horwitz, Steven M. , Inghirami, Giorgio

Mayo Clinic

American Journal of Hematology | June 13, 2025 | Volume: 100 | Issue: 9 | Pages: 1486-1501

10.1002/ajh.27736 | PMID 40510016 Get It

ABSTRACTNodal follicular helper T‐cell (T FH) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole‐exome sequencing (n = 124), transcriptomic (n = 78), and methylation (n = 40) analysis, we identified recurrent mutations in known epigenetic drivers (TET2, DNMT3A, IDH2 R172 ) and novel ones (TET3, KMT2D). TET2, IDH2 R172 , DNMT3A co‐mutated AITLs had poor prognosis (p < 0.0001). Genes regulating T‐cell receptor (TCR) signaling (CD28, PLCG1, VAV1, FYN) or activation (RHOA G17V ) or regulators of the PI3K‐pathway (PIK(3)C members, PTEN, PHLPP1, PHLPP2) were mutated. CD28 mutation/fusion was associated with poor prognosis (p = 0.02). WES of purified, neoplastic T‐cell (CD3+PD1+) demonstrated high concordance with whole tumor biopsies and validated the presence of TET2 and DNMT3A in tumor and non‐lymphoid cells, but other mutations (CD28, RHOA G17V , IDH2 R172 , PLCG1) in neoplastic cells. Integrated DNA‐methylation and mRNA expression analysis revealed epigenetic alterations in genes regulating TCR, cytokines, PI3K‐signaling, and apoptosis. RNA‐seq analysis identified fusion transcripts regulating TCR‐activation (8%), revealed a restricted TCR‐repertoire (α = 87%, β = 72%), and showed the presence of Epstein–Barr virus transcriptome (73%). GEP demonstrated the association of B‐cells or dendritic cells in the tumor milieu with prognosis (p < 0.01). RNA‐seq and WES analysis of 12 AITL‐patient‐derived‐xenografts (PDX) showed that bi‐allelic TET2 and DNMT3A mutations or sub‐clonal mutations (PLCG1, PHLPP2) propagated in sequential passages, and gene signatures related to T FH and T CM (central‐memory) were well‐maintained through passages. Gene expression signatures associated with late PDX passages (3rd–5th) were enriched with proliferation and metabolic reprogramming‐related genes and predicted prognosis in an independent AITL series. Low PHLPP2 mRNA expression predicted poor prognosis (p = 0.05) and engineered PHLPP2 or TET2 loss in CD4+ T‐cells showed enhanced PI(3)K activation, thus uncovering a therapeutic target for clinical trials.
Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer
Rami, Avina , Zhong, Caiwei , Muniz, Miguel, Khorasanchi, Adam , Fein, Daniel , Stoltenberg, Hailey, Gopalakrishan, Dharmesh, Yang, Yuanquan , Ng, Thomas S.C. , Gafita, Andrei , Jacene, Heather A. , Ravi, Praful , Muniz, Miguel , Khorasanchi, Adam , Fein, Daniel , Ng, Thomas S C , Childs, Daniel S , Xie, Wanling , Gallagher, John F. , Mohammadi, Sedra, Voter, Andrew F. , Childs, Daniel S.

Mayo Clinic

Cancers | June 12, 2025 | Volume: 17 | Issue: 12 | Pages: 1960

10.3390/cancers17121960 | PMID 40563610 Get It

Black patients with metastatic prostate cancer have higher mortality rates compared to non-Hispanic White patients. There are no data on outcomes with [177Lu]Lu-PSMA-617 (LuPSMA) across racial groups. We evaluated the association between race and outcomes with LuPSMA in a multi-institutional cohort of consecutive patients with mCRPC treated with LuPSMA. The primary outcomes were PSA-50 rate, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Statistical models were adjusted for age, number of prior therapies, sites of metastases, and baseline PSA. A total of 654 patients were included; 593 (91%) were White, 45 (7%) were Black and 16 (2%) were another non-Black minority (NBM). There were no statistically significant differences in PSA-50 rates, PSA-PFS and OS between the groups. Black and White patients treated with LuPSMA had similar clinical outcomes; efforts are needed to ensure Black and NBM patients have equal access to life prolonging therapies to narrow disparities in outcomes.
NCCN Guidelines® Insights: Survivorship, Version 2.2025
Sanft, Tara , Ansbaugh, Shannon M., Ariza‐Heredia, Ella , Ballinger, Tarah J. , Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Hill‐Kayser, Christine E. , Hock, Karen , Kline‐Quiroz, Cristina , Koura, Divya, McDonough, Allison L. , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Saidain, Ava, Schapira, Lidia , Tenne, Laura, Ah, Diane Von , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Ballinger, Tarah Jean , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Cathcart-Rake, Elizabeth , Evgeniou, Evgenios , Friedman, Debra L. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Rogers, Laura Q. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 208-217

10.6004/jnccn.2025.0028 | PMID 40499584 Get It

The NCCN Guidelines for Survivorship include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from adult-onset cancer and its treatment and provide a framework for coordination of survivorship care. They also include recommendations to help cancer survivors enhance their wellness and maintain a healthy lifestyle. These NCCN Guidelines Insights summarize the panel’s current recommendations and recent updates regarding physical activity, nutrition, and weight management for cancer survivors.
Financial buy-in does not affect outcomes of endoscopic sleeve gastroplasty: Retrospective cohort
Sayegh, Lea N. , Akiki, Karl, Annan, Karim Al , Gala, Khushboo , Ghanem, Omar M. , Sayegh, Lea Nicole , Al Annan, Karim, Abi Mosleh, Kamal , Mundi, Manpreet, Storm, Andrew C , Akiki, Karl, Salameh, Yara , Mosleh, Kamal Abi , Mundi, Manpreet S. , Dayyeh, Barham K. Abu , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | June 10, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2631-7439 | PMID 40726523 Get It

AbstractEndoscopic sleeve gastroplasty (ESG) is an effective treatment for obesity but typically is not covered by insurance. It is not known whether patients with financial investment in their endoscopic procedure are more likely to achieve and/or maintain weight loss as compared with those who have no financial buy-in. We aimed to compare treatment adherence and outcomes between patients paying out-of-pocket (OOP) and those who underwent ESG as part of any clinical trial where costs were covered by a study protocol (no payment; NP).Data were collected via retrospective chart review. One hundred sixty-four patients who had an ESG with at least 6 months of follow-up were included. Repeated measures with generalized linear model were used to evaluate weight loss at different time points after ESG and labs values at baseline and 1-year follow-up to assess for comorbidity improvement between cohorts. Compliance was evaluated by comparing exercise adherence rates.The pattern of weight loss and change in laboratory values was not different over time between the OOP group (n = 139) and NP group (n = 25). Patients lost an average of 14% (12.2–15.9) and 12.9% (9.3–16.5) of total body weight over all time points, respectively, in both groups (6, 12 and 24 months). Treatment adherence also did not differ between the groups.Having “skin in the game” by paying for ESG OOP does not correlate with better outcomes or treatment adherence, which further supports broad insurance coverage for this procedure.
Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence
Alabd, Andrew , Alabd, Andre , Lyons, Josh, Fields, Sherri, Coogle, Brianna , Kasi, Anup , Grewal, Nicholas , Kindler, Hedy L. , Starr, Jason S. , Sama, Ashwin R., Sugumar, Kavin , Hue, Jonathan J. , Lyons, Josh, Wainberg, Zev A. , Zheng, Lei , Winter, Jordan Michael

Mayo Clinic

Oncotarget | June 10, 2025 | Volume: 16 | Issue: 1 | Pages: 427-442

10.18632/oncotarget.28739 | PMID 40492845 Get It

Peritoneal Window Technique: A Novel Sutureless Technique to Decrease the Rate of Symptomatic Lymphocele after Robot-Assisted Radical Prostatectomy with Extended Pelvic Lymph Node Dissection
Qualkenbush, Eric , Lee, Yeonsoo Sara , Kahn, Amanda E. , Qosja, Neda, Hochwald, Alex, Zganjar, Andrew , Pathak, Ram , Pak, Raymond , Qualkenbush, Eric , Pak, Raymond W. , Lee, Yeonsoo S, Kahn, Amanda , Sara Lee, Yeonsoo , Pak, Ray , Myers, Amanda A.

Mayo Clinic

Journal of Endourology | June 10, 2025 | Volume: 39 | Issue: 10 | Pages: 1028-1032

10.1089/end.2025.0093 | PMID 40491420 Get It

Introduction: Robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (PLND) represents the gold standard surgical treatment for high-risk localized prostate cancer. PLND carries the risk of lymphocele formation, which can lead to complications such as deep vein thrombosis (DVT), infection, and voiding dysfunction. Many techniques have been described to minimize lymphocele formation, yet no method has seen widespread use or been described as sutureless. The objective of this study is to describe the novel, sutureless peritoneal window (PWIN) technique and assess its efficacy in lymphocele prophylaxis for extended PLND. Methods: This was a retrospective review of patients with high-risk prostate cancer undergoing RARP with extended PLND by a single surgeon from 2018 to 2024. PLND was carried out in the usual manner with bipolar cautery. PWIN technique is performed by excising a 3 × 5 cm PWIN over the lymphadenectomy bed to maintain lymphatic communication with the abdominal cavity. The primary outcome was a comparison between the incidence of symptomatic lymphoceles (SLs) with PWIN vs standard technique. SLs were defined as lymphoceles presenting with pain, DVT, voiding dysfunction, or infectious symptoms. Patients with asymptomatic lymphoceles were excluded. Results: Our study included 199 patients who underwent RARP with extended PLND. There were 46 patients (23.1%) in the standard approach group and 153 patients (76.9%) in the PWIN group. We identified 5/46 (10.9%) SLs in the standard technique, which were significantly higher than the 3/153 (2.0%) observed in the PWIN group (p = 0.017). There was no difference between the standard and PWIN cohorts regarding symptomology or treatment of their lymphocele. Conclusion: This study describes a novel, sutureless PWIN technique that significantly decreases SL after extended PLND. This technique offers a practical, time-efficient, and cost-effective alternative for lymphocele prevention. Future prospective studies are warranted to validate these findings.
Developing a Decision Support Tool to Guide Shared Decision‐Making in Bipolar Depression Treatment: Results From a Collaboration Between Clinicians and People With Lived Experience
Fuentes‐Salgado, Manuel, Gardea‐Resendez, Manuel , Ercis, Mete , Kremin, Ashley, Joyce, Jeremiah B. , Park, Jin Hong , Keeth, Nicola , Moore, Katherine M. , Betcher, Hannah K. , Yang, Padao, Williams, Mark D. , Michael, P., Frye, Mark A. , Lam, Angie, Ercis, Mete , Moore, Katherine, Betcher, Hannah, Savitz, Samuel T. , Frye, Mark , Joyce, Jeremiah , Gardea-Resendez, Manuel , Smith, Andrew, Lam, Angie, Allen, Kimberly, Kremin, Ashley, Leung, Jonathan G. , Özerdem, Ayşegül , Montori, Víctor M.

Mayo Clinic

Bipolar Disorders | June 10, 2025 | Volume: 27 | Issue: 5 | Pages: 358-364

10.1111/bdi.70037 | PMID 40491157 Get It

ABSTRACTObjectiveTo build consensus from different stakeholders on the content and digital interactivity of a shared decision making (SDM) tool to guide patient‐clinician collaborative conversations about treatment for bipolar depression.Patients and MethodsThis study was conducted between September 2022 and September 2023. In the first phase, we conducted a narrative review on pharmacological, neuromodulatory, and psychotherapeutic treatments available for bipolar depression. For each option, we assessed treatment effectiveness, side effects, need for clinical monitoring, clinical considerations, and cost. In the second phase, committees comprised of mental health clinicians and people with lived experience with bipolar disorder from a national mood disorders advocacy group identified key features and content to be included in the SDM tool. A thematic analysis of these data then contributed to populate the SDM tool.ResultsTwenty‐one evidence‐based treatment options identified from the narrative review were presented to the four convened committees (clinical, lived experience, peer council, and integrated steering committees) in five meetings. After discussions and thematic analysis, 12 outcomes of interest for each of the therapeutic interventions were delineated for inclusion in a web‐based SDM tool. A detailed description of the development process and SDM tool is provided.ConclusionThis is the first partnership between clinicians and persons with bipolar disorder lived experience charged with the development of a patient‐centered SDM tool to integrate clinical evidence with real‐world clinical practice and patient preferences for use during clinical encounters. Human‐centered design and testing in real clinical encounters will now contribute to refining the instrument and readying it for rigorous evaluation and implementation in practice.
Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer’s disease
Yang, Stephanie , Lin, Andrew A. , Shen, Hanfei , Pappalardo, Laura W., Spychalski, Griffin B. , Forsberg, Leah K. , Grant, Kiera M., Savica, Rodolfo , Reichard, R. Ross , McLean, Pamela J. , Yang, Stephanie J , Jones, David T , Dickson, Dennis W , Reichard, R Ross , Nguyen, Aivi T , Boeve, Brad , McLean, Pamela J , Rosario, Jean G. , Forsberg, Leah K., Grant, Kiera M., Buser, Joshua R. , O’Bryant, Sid, Jones, David T., Dickson, Dennis W. , Nguyen, Aivi T. , Meaney, David F. , Boeve, Bradley F. , Issadore, David

Mayo Clinic

No container title available | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.06.656900 | PMID 40661348 Get It

Abstract INTRODUCTION Robust plasma-based biomarkers to distinguish Lewy body disease (LBD) and Alzheimer’s disease (AD) are currently lacking. We applied track-etch magnetic nanopore (TENPO) sorting for enrichment of brain-derived extracellular vesicle (EV) signatures as potential biomarkers to address this gap. METHODS We analyzed plasma from 137 autopsy-confirmed patients [30 LBD, 31 AD, 30 AD/LBD, 19 AD with amygdala Lewy bodies (AD/ALB), and 27 controls], sequencing miRNAs from TENPO-isolated GluR2-positive (neuron-enriched) and GLAST-positive (astrocyte-enriched) EVs, and measuring plasma proteins (Aβ40, Aβ42, tau, p-Tau181, p-Tau231) via SIMOA. RESULTS We identified 16 GluR2+, 8 GLAST+, and 4 protein biomarkers with differential expression (false discovery rate-corrected P value < .1) between LBD and AD. A multimodal 15-feature panel classified LBD versus AD with 10-fold cross-validated accuracy = 0.95 and area under the curve (AUC) = 0.96. DISCUSSION Brain-derived EVs offer accurate and accessible miRNA biomarkers for the differential diagnosis of LBD and AD.